cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
U.S. FDA approves Tarceva for patients with advanced non-small-cell lung cancer
December 14th, 2004
OSI Pharmaceuticals, Inc., (OSIP) and Genentech, Inc., (DNA) announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Tarceva is an oral tablet indicated for daily administration. It is the only drug in the epidermal growth factor receptor class to demonstrate in a phase III clinical trial an increase in survival in advanced NSCLC patients. "The FDA approval of erlotinib marks an important new treatment option for patients in the United...
Source: cancer weekly (2004-12-14)
|
